ClinicalTrials.gg
Active, not recruitingNCT04251117Updated Sep 24, 2026Results posted

GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC

A Phase 1/2 interventional study of GNOS-PV02 and INO-9012 in HCC, sponsored by Geneos Therapeutics. Active, not recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Geneos Therapeutics · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a single-arm, open-label, multi-site Phase I/IIa study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in combination with pembrolizumab (MK-3475) in subjects with histologically or cytologically confirmed diagnosis of HCC based on pathology report.

02

Conditions studied

  • HCC
03

In context

Lead sponsor

Geneos Therapeutics is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be willing and able to provide written for the study. The subject may also provide consent for Future Biomedical Research (FBR). However, the subject may participate in the main study without participating in FBR.
  2. 18 years of age on day of signing informed consent.
  3. Have or cytologically confirmed diagnosis of HCC based on pathology report. Radiological diagnosis is valid to initiate screening pending confirmation by pathology.
  4. Have Barcelona Clinic Liver Cancer (BCLC) Stage C disease or BCLC Stage B disease not amenable to locoregional therapy, or to locoregional therapy, and not amenable to a curative treatment approach.
  5. Have a Class A liver score.
  6. Have a predicted of greater than 6 months.
  7. Have based on 1.1.
  8. Have a performance status of 0 or 1 using the Performance Scale within 7 days of first dose of study drug.
  9. Receiving or eligible for therapy with sorafenib or lenvatinib.
  10. Willing to submit a tissue sample for personalized DNA vaccine manufacturing.
  11. Patients with chronic or acute infection [as characterized by positive hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibodies (anti-HBcAb) with detectable HBV DNA (≥10 IU/ml)] must be treated with effective antiviral therapy, as per institutional practices, prior to enrollment and for the duration of the study therapy. Patients who test positive for anti-hepatitis B core (HBc) with undetectable HBV DNA (\<10 IU/ml) do not require anti-viral therapy prior to enrollment however these subjects will be tested at every cycle to monitor HBV DNA levels and initiate antiviral therapy if HBV DNA is detected (≥10 IU/ml). Subjects with chronic infection by virus (HCV), who are untreated, are allowed on study. In addition, subjects with successful HCV treatment (defined as sustained virologic response [SVR] 12 or SVR 24) are allowed, as long as 4 weeks have passed between completion of HCV therapy and start of study drug. Subjects receiving antiviral therapy during TKI may be enrolled.
  12. Women of (WOCBP) must have a negative urine or serum pregnancy test for the patient to be eligible for trial enrolment.
  13. Be willing to use an adequate method of for the course of the study through 150 days after the last dose of study drug (male and female subjects of childbearing potential).

    Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.

  14. Demonstrate adequate organ function

Exclusion criteria

Exclusion Criteria:

  1. Is currently participating and receiving study drug or has participated in a study of an agent and received study drug or used an investigation device, within 4 weeks of the first dose of treatment. Subjects must also have recovered from associated therapy (i.e., to Grade ≤1 or baseline) and from AEs due to any prior therapy.
  2. Has received sorafenib or lenvatinib within 14 days of first dose of study drug.
  3. Has had esophageal or gastric variceal bleeding within the last 6 months. If suspected, subjects will be screened for esophageal varices. If varices are present, they should be treated according to institutional standards before starting study treatment.
  4. Has clinically apparent ascites on physical examination. Note: only ascites detectable on imaging studies is allowed.
  5. Evidence of portal vein invasion based on imaging is allowed pending subjects meet laboratory criteria for enrollment.
  6. Has had encephalopathy in the last 6 months. Subjects on rifaximin or lactulose to control their encephalopathy are not allowed.
  7. Had a solid organ or hematologic transplant.
  8. Had prior systemic therapy for HCC other than sorafenib or lenvatinib.
  9. Has active disease that has required systemic treatment in past 2 years (i.e., with use of disease-modifying agents, , or drugs). Replacement therapy (e.g., T4, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  10. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor.
  11. Has received locoregional therapy to liver (transarterial chemoembolization [TACE], transarterial embolization [TAE], radiation, radioembolization, or ablation) or major surgery to liver or other site within 3 weeks prior to the first dose of study drug. Minor surgery (e.g., simple excision, tooth extraction) must have occurred at least 7 days prior to the first dose of study drug (Cycle 1, Day 1). Subjects must have recovered adequately (i.e., Grade ≤1 or baseline) from the toxicity and/or complications from any intervention prior to starting therapy.
  12. Has a diagnosed additional within 5 years prior to first dose of study drug, with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or curatively resected in situ cervical and/or breast cancers. Subjects with history of early-stage prostate cancer that has been curatively treated or appropriate for observation may be enrolled.
  13. Has radiographically detectable (even if asymptomatic and/or previously treated) central nervous system (CNS) and/or carcinomatous meningitis, as assessed by local site investigator.
  14. Has a known history of, or any evidence of, interstitial lung disease or active non- infectious pneumonitis.
  15. Has an active infection requiring systemic therapy.
  16. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator, including dialysis.
  17. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
  18. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 150 days after the last dose of study drug.
  19. Has received prior immunotherapy including anti-programmed death (PD) 1, anti-programmed death ligand (PD-L)-1, or agents, or personalized therapies such as adoptive cell therapy or neoantigen-based vaccine.
  20. Has a known history of (HIV) (HIV I/II antibodies).
  21. Has untreated active virus (HBV), unless planned antiviral therapy during TKI.

    Note: Patients with HBV infection, characterized by positive HBsAg and/or HBcAb with detectable HBV DNA (≥10 IU/ml or above the limit of detection per local lab standard), must be treated with antiviral therapy as per institutional practice to ensure adequate viral suppression (HBV DNA ≤2000 IU/mL) prior to treatment with the study drug. Patients who test positive for HBcAg with undetectable HBV DNA (\<10 IU/ml or under the limit of detection per local lab standard) do not require anti-viral therapy prior to enrollment.

  22. Has received a within 30 days of planned start of study treatment (Cycle 1, Day 1).

    Note: The killed virus vaccines used for seasonal influenza vaccines for injection are allowed; however intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed. Non-live COVID-19 vaccines are allowed.

  23. Any for treatment with the CELLECTRA® 2000 Device:

    Less than two acceptable sites available for ID injection and EP considering the deltoid and anterolateral quadriceps muscles:

    1. Tattoos, keloids or hypertrophic scars located within 2 cm of intended administration site.
    2. Implantable-Cardioverter-defibrillator (ICD) or pacemaker (to prevent a life-threatening arrhythmia) that is located ipsilateral to the deltoid injection site (unless deemed acceptable by a cardiologist).
    3. Any metal implants or implantable medical device within the intended treatment site (i.e. electroporation area).
  24. Has no mutations detected after sequencing of the tumor
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    GNOS-PV02 + INO-9012 + Pembrolizumab

    First line therapy with standard of care tyrosine kinase inhibitors (TKI) during which patient-specific GNOS-PV02 will be manufactured. GNOS-PV02 + INO-9012 + Pembrolizumab will be administered upon disease progression or intolerance to TKI.

    Biological: GNOS-PV02 · Biological: INO-9012 · Drug: Pembrolizumab · Device: CELLECTRA®2000 EP Device

Interventions

  • BiologicalGNOS-PV02

    GNOS-PV02 delivered by intradermal injection and electroporation

  • BiologicalINO-9012

    INO-9012 delivered by intradermal injection and electroporation

  • Pembrolizumab administered as an intravenous (IV) infusion

  • DeviceCELLECTRA®2000 EP Device

    CELLECTRA® 2000 Device is a system indicated for use to enhance the uptake and expression of plasmid-based biologics in order to enhance vaccine efficacy.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Related Adverse Events

    Incidence of treatment-related adverse events (TRAEs), defined as adverse events deemed possibly, probably, or definitely related to study treatment (PTCV, IL-12, electroporation and/or immune checkpoint inhibitor), with onset on or after the first dose and graded according to CTCAE version 5.0.

    Time frame: From first study drug administration to approximately 57 months

  2. Neoantigen-Specific T-Cell Response

    Neoantigen-specific T-cell immune response measured using interferon-gamma (IFNγ) ELISpot assays in peripheral blood mononuclear cells (PBMCs). Immune responses were assessed as the magnitude and presence of vaccine-induced T-cell responses to patient-specific neoantigens.

    Time frame: From baseline (pretreatment) through on-treatment assessments (approximately up to Week 12), with additional exploratory follow-up time points.

  3. Immunogenicity of a Personalized Neoantigen DNA Vaccine as Measured by T-cell Activation and Cytolytic Cell Phenotype in PBMCs Using Flow Cytometry

    Immunogenicity assessed by flow cytometry in peripheral blood mononuclear cells (PBMCs), including T-cell activation (CD69+CD107a+), proliferation (Ki67+) and cytolytic phenotype (GZMA+PRF1+) in CD4+ and CD8+ T-cell populations following stimulation with personalized neoantigen vaccine (PTCV) compared to unstimulated control. Results are summarized as mean percentage of marker-positive T-cell populations among CD4+ or CD8+ T cells. Measurements were performed under unstimulated and antigen-stimulated conditions and data were averaged across the timepoints for the 4 subjects.

    Time frame: Assessments completed at Weeks 9 or Weeks 12 post-treatment for 4 subjects.

Secondary outcomes

  1. Objective Response Rate (ORR)

    Objective response rate, defined as the proportion of patients achieving a complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as assessed by investigator review.

    Time frame: From first dose to first documented disease progression or death, up to 60 months

  2. Anti-tumor Activity as Measured by Objective Response Rate (ORR) by iRECIST

    Objective response rate (ORR) defined as the proportion of patients achieving an immune complete response (iCR) or immune partial response (iPR) according to immune Response Evaluation Criteria in Solid Tumors (iRECIST), as assessed by investigator review.

    Time frame: From treatment initiation to first documented disease progression or death. Up to 60 months.

  3. Anti-tumor Activity as Measured by Duration of Response (DOR)

    Duration of response defined as the time from first documented confirmed response (complete or partial response) to disease progression or death from any cause, whichever occurred first, assessed according to RECIST version 1.1 using Kaplan-Meier estimation.

    Time frame: From first documented response until disease progression or death, assessed up to approximately 5 years.

  4. Disease Control Rate (DCR)

    Disease control rate defined as the proportion of participants achieving a complete response (CR), partial response (PR), or stable disease (SD) according to RECIST version 1.1, as assessed by investigator review.

    Time frame: From baseline through disease progression; dosing can occur for up to 5 years. Tumor assessments performed every 9 weeks through Week 54 and every 12 weeks thereafter until progression or study end (up to 5 years).

  5. Progression-Free Survival (PFS)

    Progression-free survival defined as the time from first dose of study treatment to the first documented radiographic disease progression according to RECIST version 1.1 or death from any cause, whichever occurred first.

    Time frame: From first dose of study treatment until disease progression or death, assessed up to approximately 5 years.

  6. Anti-tumor Activity as Measured by Progression Free Survival (PFS) as Assessed by iRECIST

    Progression-free survival (PFS) defined as the time from first dose of study treatment to confirmed progressive disease or death from any cause, whichever occurred first, assessed according to immune Response Evaluation Criteria in Solid Tumors (iRECIST) using Kaplan-Meier estimation.

    Time frame: From first dose of study treatment until confirmed disease progression or death, assessed up to approximately 5 years.

  7. Overall Survival (OS)

    Overall survival defined as the time from first dose of study treatment to death from any cause.

    Time frame: From first dose of study treatment until death from any cause, with follow up conducted for up to approximately 5 years.

07

Results

Posted Sep 24, 2026

Participant flow

Male and female subjects with advanced HCC currently receiving or scheduled to receive first-line treatment with sorafenib or lenvatinib, will be enrolled in this study. Combination therapy with GNOS-PV02 and pembrolizumab will begin after discontinuation of first-line lenvatinib or sorafenib. Enrollment period: 3 years.

Participant flow — Overall Study
MilestoneGNOS-PV02 + INO-9012 Followed by Electroporation in Combination With Pembrolizumab
Started36
Completed34
Not completed2
Withdrew: Adverse event2

Outcome measures

PrimaryIncidence of Treatment-Related Adverse Events

Incidence of treatment-related adverse events (TRAEs), defined as adverse events deemed possibly, probably, or definitely related to study treatment (PTCV, IL-12, electroporation and/or immune checkpoint inhibitor), with onset on or after the first dose and graded according to CTCAE version 5.0.

Time frame:
From first study drug administration to approximately 57 months
Reported as:
Number · participants
Incidence of Treatment-Related Adverse Events
participantsGNOSPV02 + pIL12 + Pembrolizumab
Participants with Grade 1 Treatment-Related Adverse Events25
Participants with Grade 2 Treatment-Related Adverse Events13
Participants with Grade 3 Treatment-Related Adverse Events2
Participants with Grade 4 Treatment-Related Adverse Events0
Participants with Grade 5 Treatment-Related Adverse Events0
PrimaryNeoantigen-Specific T-Cell Response

Neoantigen-specific T-cell immune response measured using interferon-gamma (IFNγ) ELISpot assays in peripheral blood mononuclear cells (PBMCs). Immune responses were assessed as the magnitude and presence of vaccine-induced T-cell responses to patient-specific neoantigens.

Time frame:
From baseline (pretreatment) through on-treatment assessments (approximately up to Week 12), with additional exploratory follow-up time points.
Reported as:
Count of participants · Participants
Neoantigen-Specific T-Cell Response
ParticipantsGNOSPV02 + pIL12 + Pembrolizumab
Neoantigen-Specific T-Cell Response19
PrimaryImmunogenicity of a Personalized Neoantigen DNA Vaccine as Measured by T-cell Activation and Cytolytic Cell Phenotype in PBMCs Using Flow Cytometry

Immunogenicity assessed by flow cytometry in peripheral blood mononuclear cells (PBMCs), including T-cell activation (CD69+CD107a+), proliferation (Ki67+) and cytolytic phenotype (GZMA+PRF1+) in CD4+ and CD8+ T-cell populations following stimulation with personalized neoantigen vaccine (PTCV) compared to unstimulated control. Results are summarized as mean percentage of marker-positive T-cell populations among CD4+ or CD8+ T cells. Measurements were performed under unstimulated and antigen-stimulated conditions and data were averaged across the timepoints for the 4 subjects.

Time frame:
Assessments completed at Weeks 9 or Weeks 12 post-treatment for 4 subjects.
Reported as:
Mean · Percent (%)
Immunogenicity of a Personalized Neoantigen DNA Vaccine as Measured by T-cell Activation and Cytolytic Cell Phenotype in PBMCs Using Flow Cytometry
Percent (%)GNOS-PV02 + INO-9012 Followed by Electroporation in Combination With Pembrolizumab
CD4+ T-cell activation (CD69+CD107a+) - Unstimulated0.53 (0.26 to 0.75)
CD4+ T-cell activation (CD69+CD107a+) - Stimulated2.075 (0.35 to 5.215)
CD8+ T-cell activation (CD69+CD107a+) - Unstimulated0.258 (0.11 to 0.45)
CD8+ T-cell activation (CD69+CD107a+) - Stimulated0.6165 (0.213 to 0.95)
CD4+ T-cell proliferation (Ki67+) - Unstimulated1.3775 (0.65 to 2.33)
CD4+ T-cell proliferation (Ki67+) - Stimulated3.20025 (2.103 to 4.88)
CD8+ T-cell proliferation (Ki67+) - Unstimulated1.335 (0.89 to 1.81)
CD8+ T-cell proliferation (Ki67+) - Stimulated4.21275 (1.445 to 7.608)
CD8+ cytolytic phenotype (Ki67+GZMA+PRF1+) - Unstimulated0.13575 (0 to 0.34)
CD8+ cytolytic phenotype (Ki67+GZMA+PRF1+) - Stimulated0.41025 (0.025 to 0.948)
CD8+ activation/cytolytic phenotype (CD69+CD107a+GZMA+PRF1+) - Unstimulated0.17725 (0.079 to 0.29)
CD8+ activation/cytolytic phenotype (CD69+CD107a+GZMA+PRF1+) - Stimulated0.38075 (0.105 to 0.658)
SecondaryObjective Response Rate (ORR)

Objective response rate, defined as the proportion of patients achieving a complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as assessed by investigator review.

Time frame:
From first dose to first documented disease progression or death, up to 60 months
Reported as:
Count of participants · Participants
Objective Response Rate (ORR)
ParticipantsGNOSPV02 + pIL12 + Pembrolizumab
Complete Response3
Partial Response6
Stable Disease11
Progressive Disease14
Not Evaluable2
Statistical analysis
  • GNOSPV02 + pIL12 + Pembrolizumab · Exact binomial test, one-sided · p = 0.031One-sided hypothesis test evaluating whether the observed ORR exceeds the historical control value of 16.9%.
SecondaryAnti-tumor Activity as Measured by Objective Response Rate (ORR) by iRECIST

Objective response rate (ORR) defined as the proportion of patients achieving an immune complete response (iCR) or immune partial response (iPR) according to immune Response Evaluation Criteria in Solid Tumors (iRECIST), as assessed by investigator review.

Time frame:
From treatment initiation to first documented disease progression or death. Up to 60 months.
Reported as:
Number · Percent
Anti-tumor Activity as Measured by Objective Response Rate (ORR) by iRECIST
PercentGNOS PV02 + pIL 12 + Pembrolizumab
Anti-tumor Activity as Measured by Objective Response Rate (ORR) by iRECIST0.0 (0.0 to 9.7)
SecondaryAnti-tumor Activity as Measured by Duration of Response (DOR)

Duration of response defined as the time from first documented confirmed response (complete or partial response) to disease progression or death from any cause, whichever occurred first, assessed according to RECIST version 1.1 using Kaplan-Meier estimation.

Time frame:
From first documented response until disease progression or death, assessed up to approximately 5 years.
Reported as:
Median · Months
Anti-tumor Activity as Measured by Duration of Response (DOR)
MonthsGNOS PV02 + pIL 12 + Pembrolizumab
Anti-tumor Activity as Measured by Duration of Response (DOR)NA (13.4 to —)
SecondaryDisease Control Rate (DCR)

Disease control rate defined as the proportion of participants achieving a complete response (CR), partial response (PR), or stable disease (SD) according to RECIST version 1.1, as assessed by investigator review.

Time frame:
From baseline through disease progression; dosing can occur for up to 5 years. Tumor assessments performed every 9 weeks through Week 54 and every 12 weeks thereafter until progression or study end (up to 5 years).
Reported as:
Number · Percent
Disease Control Rate (DCR)
PercentGNOS PV02 + pIL 12 + Pembrolizumab
Disease Control Rate (DCR)55.6 (38.1 to 72.1)
SecondaryProgression-Free Survival (PFS)

Progression-free survival defined as the time from first dose of study treatment to the first documented radiographic disease progression according to RECIST version 1.1 or death from any cause, whichever occurred first.

Time frame:
From first dose of study treatment until disease progression or death, assessed up to approximately 5 years.
Reported as:
Median · Months
Progression-Free Survival (PFS)
MonthsGNOSPV02 + pIL12 + Pembrolizumab
Progression-Free Survival (PFS)4.5 (2.3 to 14.9)
SecondaryAnti-tumor Activity as Measured by Progression Free Survival (PFS) as Assessed by iRECIST

Progression-free survival (PFS) defined as the time from first dose of study treatment to confirmed progressive disease or death from any cause, whichever occurred first, assessed according to immune Response Evaluation Criteria in Solid Tumors (iRECIST) using Kaplan-Meier estimation.

Time frame:
From first dose of study treatment until confirmed disease progression or death, assessed up to approximately 5 years.
Reported as:
Median · Months
Anti-tumor Activity as Measured by Progression Free Survival (PFS) as Assessed by iRECIST
MonthsGNOS PV02 + pIL 12 + Pembrolizumab
Anti-tumor Activity as Measured by Progression Free Survival (PFS) as Assessed by iRECIST20.1 (5.4 to NA)
SecondaryOverall Survival (OS)

Overall survival defined as the time from first dose of study treatment to death from any cause.

Time frame:
From first dose of study treatment until death from any cause, with follow up conducted for up to approximately 5 years.
Reported as:
Median · Months
Overall Survival (OS)
MonthsGNOS PV02 + pIL 12 + Pembrolizumab
Overall Survival (OS)18.3 (9.0 to 30.2)

Adverse events

Collected over From first study drug administration to approximately 57 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GNOS-PV02 + INO-9012 Followed by Electroporation in Combination With Pembrolizumab24/36 (66.7%)19/36 (52.8%)27/36 (75%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventGNOS-PV02 + INO-9012 Followed by Electroporation in Combination With Pembrolizumab
Abdominal painGastrointestinal disorders2/36
Lower respiratory tract infectionInfections and infestations2/36
PneumoniaInfections and infestations2/36
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/36
AnaemiaBlood and lymphatic system disorders2/36
Abdominal pain upperGastrointestinal disorders1/36
Anal fissureGastrointestinal disorders1/36
AscitesGastrointestinal disorders1/36
ColitisGastrointestinal disorders1/36
Faeces discolouredGastrointestinal disorders1/36
Most frequent other events
Showing 10 of 62
Most frequent other events
EventGNOS-PV02 + INO-9012 Followed by Electroporation in Combination With Pembrolizumab
FatigueGeneral disorders14/36
DiarrhoeaGastrointestinal disorders14/36
Decreased appetiteMetabolism and nutrition disorders10/36
Abdominal painGastrointestinal disorders9/36
ArthralgiaMusculoskeletal and connective tissue disorders9/36
Back painMusculoskeletal and connective tissue disorders8/36
HeadacheNervous system disorders8/36
COVID-19Infections and infestations8/36
Upper respiratory tract infectionInfections and infestations8/36
NauseaGastrointestinal disorders7/36

Baseline characteristics

The baseline analysis population consisted of 36 patients with advanced hepatocellular carcinoma who initiated study treatment and formed the modified intention-to-treat population.

Age, Categorical
Age, Categorical(Participants)Single Arm, Interventional
<=18 years0
Between 18 and 65 years16
>=65 years20
Age, Continuous
Age, Continuous(Years)Single Arm, Interventional
Median68 (40 to 83)
Sex: Female, Male
Sex: Female, Male(Participants)Single Arm, Interventional
Female11
Male25
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Single Arm, Interventional
Hispanic or Latino0
Not Hispanic or Latino36
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Single Arm, Interventional
United States8
New Zealand28
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Single Arm, Interventional
American Indian or Alaska Native0
Asian6
Native Hawaiian or Pacific Islander2
Black or African American1
White21
More than one race0
Unknown or Not Reported0
Other6
ECOG Performance Status
ECOG Performance Status(Participants)Single Arm, Interventional
ECOG 08
ECOG 114
ECOG 210
ECOG 33
ECOG 40
ECOG 50
UNKNOWN1
Child-Pugh Classification
Child-Pugh Classification(Participants)Single Arm, Interventional
Class A36
Class B or C0

7 further baseline measures are reported on the registry.

08

Study locations

3 sites
09

References and documents

Publications

  • Yarchoan M, Gane EJ, Marron TU, Perales-Linares R, Yan J, Cooch N, Shu DH, Fertig EJ, Kagohara LT, Bartha G, Northcott J, Lyle J, Rochestie S, Peters J, Connor JT, Jaffee EM, Csiki I, Weiner DB, Perales-Puchalt A, Sardesai NY. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial. Nat Med. 2024 Apr;30(4):1044-1053. doi: 10.1038/s41591-024-02894-y. Epub 2024 Apr 7. PubMed 38584166 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2020 to primary completion in Nov 2024, 56 months.

Results were first posted in Sep 2026, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2020
First posted
Jan 31, 2020
StartActual
Mar 1, 2020
Primary completionActual
Nov 29, 2024
CompletionEst.
Nov 29, 2028
Results first posted
Sep 24, 2026
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04251117
Lead sponsor
Geneos Therapeutics
Responsible party
Sponsor
First posted
Jan 31, 2020
Start date
Mar 1, 2020
Primary completion
Nov 29, 2024
Completion
Nov 29, 2028 (estimated)
Results posted
Sep 24, 2026
Last update
Sep 24, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rocakinogene sifuplasmid

Start the discussion